TrioBiotics Pharma AG
Triton Biopharma AG: Marcus Tius joins International Research Team
Triton Biopharma AG / Change of Personnel Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- ZUG, Switzerland - April 9, 2009 - TRITON BIOPHARMA AG (Frankfurt: 4ON) today announced the addition of Dr. Marcus A. Tius, Ph.D. as a member of the International Research Team to conduct contract natural products synthesis for Triton BioPharma LLC, an operating subsidiary and R&D company of Triton BioPharma AG. Dr. Tius is presently the Director of the Natural Products and Cancer Biology Program at the Cancer Research Center of Hawaii and a Professor of Chemistry at the University of Hawaii at Manoa. He has particular expertise in the areas of total synthesis and the development of new synthetic methods. Dr. Tius has received numerous honors and awards, including the Roche Distinguished Lecturer from Colorado State University, CREST Fellowship in 2001, the Japan Society for the Promotion of Science Fellowship in 1998, and several distinctions in teaching excellence. He earned both a Ph.D. an M.S. in Chemistry from Harvard University, in addition to a B.A. in Chemistry & Mathematics of Dartmouth College in Hanover, New Hampshire. Dr. Tius is an author of numerous peer-reviewed journal articles, paper presentations and book chapters. He served as a consultant for the Hawaii Biotechnology Group (HBG) and was a member of the academic team that collaborated with Eli Lilly Co. on the development of the cryptophycins. 'Prof. Tius' tremendous expertise on the scaleable total synthesis of complex natural products is unmatched and we are proud and honored to have him join our research team. In addition, Dr. Tius' experience in drug development with the University of Hawaii's Cancer Research Center and Eli Lilly brings a broad and valuable scope of expertise to Triton's product development team' said Dr. Mark T. Hamann, Ph.D., CSO of Triton BioPharma AG. Angelo Boujos, President & CEO of Triton BioPharma AG, said, 'Building strong partnerships with academia and industry is a key strategy in Triton's drug discovery and global business development vision.' Mr. Boujos continued, 'We are pleased to have such highly experienced researchers and consultants working to develop new and better treatments for a suite of disease targets from highly novel and unique natural product structural classes.' About Triton BioPharma AG Triton BioPharma AG is a holding company and is only active through its wholly-owned subsidiaries, Triton BioPharma SARL and Triton BioPharma LLC. These subsidiary companies are responsible for all of Triton's biotechnology operations and R&D activities in the discovery, development, and commercialization of novel drug leads from marine sources for the global market. Triton's current pipeline includes advanced preclinical candidates in the treatment of neuropsychiatric disorders, including depression and anxiety, inflammation, infectious diseases and cancer. The company was founded in 2008 and has its corporate office in Toronto, Canada. For more information, visit www.tritonbiopharma.com Contact: Investor Relations Europe: Milestone Media AG, Zug, Switzerland Phone: +41 (0)41 5000 769 Fax: +41 (0)41 5000 728 E-mail: info@milestonemedia.ch 09.04.2009 Financial News transmitted by DGAP ----------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden